Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR20(NAP)-T in Relapsed/Refractory B Cell Lymphoma
NCT06002659Phase 2Recruiting
- Sponsor
- Uppsala University
- Start
- May 2024
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ELC-301 in B cell lymphoma, sponsored by Uppsala University. Started May 2024; status: recruiting.
02
Drugs
ELC-301
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT06002659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06002659.